Research programme: protective autoimmunity enhancer - Proneuron Biotechnologies
Alternative Names: PN-277Latest Information Update: 16 Jul 2016
At a glance
- Originator Proneuron Biotechnologies
- Class Oligopeptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders; Glaucoma; Parkinson's disease; Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA (Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in USA (Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (SC, Injection)